Skip Navigation
NCI banner National Cancer Institute U.S. National Institutes of Health National Cancer Institute
Chromosomes
  • Tools
  • Genetic and Physical SNP Maps
  • SNP500Cancer
Cancer Genome Characterization Initiative

Visit the database of genomic characterization data for multiple tumor types.

Association List

Go to page: 1 2 [Full Text] NextPage
Displaying Investigations 1 to 100 of 147 found
From 17 References


Arnould et al 1999, Hum Mol Genet
  Acute promyelocytic leukemia (FAB type M3)
STAT5B/RARA
t(17;17)(q21;q21)

Asmann et al 2011, Nucleic Acids Res
  Adenocarcinoma Breast
ATXN7L3/FAM171A2
t(17;17)(q21;q21)

Atak et al 2013, PLoS Genet
  Acute lymphoblastic leukemia/lymphoblastic lymphoma
KANSL1/ARL17A
t(17;17)(q21;q21)
T-Lineage
  Acute lymphoblastic leukemia/lymphoblastic lymphoma
STAT5B/STAT3
t(17;17)(q21;q21)
T-Lineage
  Acute lymphoblastic leukemia/lymphoblastic lymphoma
SGCA/PPP1R9B
t(17;17)(q21;q21)
T-Lineage

Babiceanu et al 2016, Nucleic Acids Res
  Nonneoplastic epithelial disorder/lesion Thyroid
KANSL1/ARL17A
t(17;17)(q21;q21)
  Nonneoplastic epithelial disorder/lesion Gallbladder/Biliary system
KANSL1/ARL17A
t(17;17)(q21;q21)
  Nonneoplastic epithelial disorder/lesion Bladder
KANSL1/ARL17A
t(17;17)(q21;q21)
  Nonneoplastic hematologic disorder/lesion Lymph node
KANSL1/ARL17A
t(17;17)(q21;q21)
  Nonneoplastic epithelial disorder/lesion Adrenal
KANSL1/ARL17A
t(17;17)(q21;q21)
  Nonneoplastic epithelial disorder/lesion Oesophagus
KANSL1/ARL17A
t(17;17)(q21;q21)
  Nonneoplastic epithelial disorder/lesion Thyroid
KANSL1/ARL17B
t(17;17)(q21;q21)
  Nonneoplastic epithelial disorder/lesion Gallbladder/Biliary system
KANSL1/ARL17B
t(17;17)(q21;q21)
  Nonneoplastic epithelial disorder/lesion Bladder
KANSL1/ARL17B
t(17;17)(q21;q21)
  Nonneoplastic hematologic disorder/lesion Lymph node
KANSL1/ARL17B
t(17;17)(q21;q21)
  Nonneoplastic epithelial disorder/lesion Adrenal
KANSL1/ARL17B
t(17;17)(q21;q21)
  Nonneoplastic epithelial disorder/lesion Skin
KANSL1/ARL17B
t(17;17)(q21;q21)
  Nonneoplastic epithelial disorder/lesion Oesophagus
KANSL1/ARL17B
t(17;17)(q21;q21)

Barros-Silva et al 2013, Neoplasia
  Adenocarcinoma Prostate
UBTF/ETV4
t(17;17)(q21;q21)

Hu et al 2018, Nucleic Acids Res
  Adenocarcinoma Prostate
AARSD1/CCR7
t(17;17)(q21;q21)
  Adenocarcinoma Stomach
ABCC3/XYLT2
t(17;17)(q21;q21)
  Adenocarcinoma Stomach
ABCC3/ACSF2
t(17;17)(q21;q21)
  Adenocarcinoma Stomach
ARHGAP27/KANSL1
t(17;17)(q21;q21)
  Malignant melanoma Skin
ATP6V0A1/STAT5B
t(17;17)(q21;q21)
  Adenocarcinoma Gallbladder/Biliary system
CASC3/THRA
t(17;17)(q21;q21)
  Adenocarcinoma Liver
CDC27/SNF8
t(17;17)(q21;q21)
  Adenocarcinoma Stomach
CDC6/JUP
t(17;17)(q21;q21)
  Adenocarcinoma Stomach
CDK5RAP3/SP2
t(17;17)(q21;q21)
  Malignant epithelial tumor, special type Uterus, corpus
CRHR1/SPOP
t(17;17)(q21;q21)
  Adenocarcinoma Stomach
DHX58/FAM134C
t(17;17)(q21;q21)
  Adenocarcinoma Large intestine
DHX8/PPY
t(17;17)(q21;q21)
  Adenocarcinoma Prostate
EFTUD2/DUSP3
t(17;17)(q21;q21)
  Adenocarcinoma Kidney
EFTUD2/GFAP
t(17;17)(q21;q21)
  Malignant epithelial tumor, special type Uterus, corpus
EFTUD2/PLEKHM1
t(17;17)(q21;q21)
  Adenocarcinoma Ovary
EZH1/MAP3K14
t(17;17)(q21;q21)
  Adenocarcinoma Stomach
FKBP10/KRT40
t(17;17)(q21;q21)
  Adenocarcinoma Adrenal
GJC1/SKAP1
t(17;17)(q21;q21)
  Adenocarcinoma Prostate
GPATCH8/KRT25
t(17;17)(q21;q21)
  Transitional cell carcinoma Bladder
JUP/ACLY
t(17;17)(q21;q21)
  Mesenchymal tumor, NOS Unknown site
KANSL1/PYY
t(17;17)(q21;q21)
  Transitional cell carcinoma Bladder
KANSL1/NSF
t(17;17)(q21;q21)
  Adenocarcinoma Adrenal
KIF18B/C1QL1
t(17;17)(q21;q21)
  Adenocarcinoma Prostate
KIF18B/TUBG1
t(17;17)(q21;q21)
  Adenocarcinoma Oesophagus
KIF18B/C17orf104
t(17;17)(q21;q21)
  Adenocarcinoma Stomach
KRT19/IKZF3
t(17;17)(q21;q21)
  Malignant epithelial tumor, special type Uterus, corpus
LUC7L3/MYCBPAP
t(17;17)(q21;q21)
  Adenocarcinoma Stomach
LUC7L3/CACNA1G
t(17;17)(q21;q21)
  Adenocarcinoma Uterus, corpus
LUC7L3/ACSF2
t(17;17)(q21;q21)
  Squamous cell carcinoma Uterus, cervix
MAP3K14/ACBD4
t(17;17)(q21;q21)
  Adenocarcinoma Oesophagus
MBTD1/THRA
t(17;17)(q21;q21)
  Adenocarcinoma Breast
MBTD1/UTP18
t(17;17)(q21;q21)
  Adenocarcinoma Oesophagus
MED24/NR1D1
t(17;17)(q21;q21)
  Adenocarcinoma Stomach
NAGS/PYY
t(17;17)(q21;q21)
  Adenocarcinoma Prostate
NBR1/C17orf104
t(17;17)(q21;q21)
  Adenocarcinoma Adrenal
NFE2L1/NPEPPS
t(17;17)(q21;q21)
  Adenocarcinoma Kidney
NMT1/HIGD1B
t(17;17)(q21;q21)
  Malignant melanoma Skin
NSF/NFE2L1
t(17;17)(q21;q21)
  Adenocarcinoma Uterus, corpus
P3H4/ACLY
t(17;17)(q21;q21)
  Adenocarcinoma Stomach
PRR15L/CBX1
t(17;17)(q21;q21)
  Mesothelioma Pleura
PRR15L/CDK5RAP3
t(17;17)(q21;q21)
  Adenocarcinoma Uterus, corpus
SCRN2/CBX1
t(17;17)(q21;q21)
  Malignant epithelial tumor, special type Uterus, corpus
SCRN2/GIP
t(17;17)(q21;q21)
  Adenocarcinoma Ovary
SKAP1/HOXB9
t(17;17)(q21;q21)
  Adenocarcinoma Uterus, corpus
SKAP1/HOXB6
t(17;17)(q21;q21)
  Adenocarcinoma Prostate
SLC25A39/EFCAB13
t(17;17)(q21;q21)
  Adenocarcinoma Large intestine
SMARCE1/RARA
t(17;17)(q21;q21)
  Squamous cell carcinoma Uterus, cervix
SNX11/MED24
t(17;17)(q21;q21)
  Malignant epithelial tumor, special type Uterus, corpus
SNX11/SNF8
t(17;17)(q21;q21)
  Adenocarcinoma Liver
SPATA20/EPN3
t(17;17)(q21;q21)
  Adenocarcinoma Breast
SPOP/RARA
t(17;17)(q21;q21)
  Adenocarcinoma Oesophagus
SPOP/EFCAB13
t(17;17)(q21;q21)
  Adenocarcinoma Adrenal
SPOP/AARSD1
t(17;17)(q21;q21)
  Adenocarcinoma Prostate
STAT3/ETV4
t(17;17)(q21;q21)
  Malignant epithelial tumor, special type Uterus, corpus
THRA/KRT20
t(17;17)(q21;q21)
  Adenocarcinoma Stomach
TMEM99/KRT28
t(17;17)(q21;q21)
  Squamous cell carcinoma Lung
TNS4/CCR7
t(17;17)(q21;q21)
  Adenocarcinoma Stomach
WIPF2/PSMD3
t(17;17)(q21;q21)
  Adenocarcinoma Stomach
WIPF2/THRA
t(17;17)(q21;q21)
  Adenocarcinoma Prostate
WIPF2/RAMP2
t(17;17)(q21;q21)
  Malignant epithelial tumor, special type Uterus, corpus
WIPF2/XYLT2
t(17;17)(q21;q21)
  Squamous cell carcinoma Uterus, cervix
WIPF2/DBF4B
t(17;17)(q21;q21)
  Adenocarcinoma Adrenal
WIPF2/ZPBP2
t(17;17)(q21;q21)

Kloosterman et al 2017, Cancer Res
  Adenocarcinoma Large intestine
SMARCE1/KRT222
t(17;17)(q21;q21)

Kusakabe et al 2008, Eur J Haematol
  Acute promyelocytic leukemia (FAB type M3)
STAT5B/RARA
t(17;17)(q21;q21)

Natrajan et al 2014, J Pathol
  Adenocarcinoma Breast
NSF/EFCAB13
t(17;17)(q21;q21)

Nome et al 2013, Transl Oncol
  Adenocarcinoma Large intestine
SPAG9/MBTD1
t(17;17)(q21;q21)

Ojesina et al 2014, Nature
  Squamous cell carcinoma Uterus, cervix
STAT3/PTRF
t(17;17)(q21;q21)

Robinson et al 2011, Nat Med
  Adenocarcinoma Breast
KANSL1/MBTD1
t(17;17)(q21;q21)

Robinson et al 2017, Nature
  Adenocarcinoma Breast
FAM134C/BRCA1
t(17;17)(q21;q21)

Sakarya et al 2012, PLoS Comput Biol
  Adenocarcinoma Breast
ATXN7L3/FAM171A2
t(17;17)(q21;q21)

Shah et al 2013, BMC Genomics
  Astrocytoma, grade III-IV/Glioblastoma Brain
THRA/GSDMA
t(17;17)(q21;q21)

Wen et al 2012, PLoS One
  Acute myeloid leukemia, NOS
KANSL1/ARL17B
t(17;17)(q21;q21)
  Acute myeloid leukemia, NOS
DHX8/ETV4
t(17;17)(q21;q21)

Yoshihara et al 2015, Oncogene
  Adenocarcinoma Thyroid
KAT7/IGF2BP1
t(17;17)(q21;q21)
  Malignant melanoma Skin
TMEM106A/NMT1
t(17;17)(q21;q21)
  Adenocarcinoma Prostate
CDC27/MYL4
t(17;17)(q21;q21)
  Malignant melanoma Skin
SKAP1/CALCOCO2
t(17;17)(q21;q21)
  Adenocarcinoma Ovary
MED24/KRT40
t(17;17)(q21;q21)
  Adenocarcinoma Prostate
PRR15L/KCNH4
t(17;17)(q21;q21)
  Adenocarcinoma Prostate
PRR15L/RAB5C
t(17;17)(q21;q21)

NextPage